Reliably evaluate the proarrhythmic and cardiotoxic liabilities of your compounds.

• Non-GLP hERG screening to eliminate cardiac risk liability.
• Comprehensive in vitro proarrhythmia assay.
• hiPSC-derived cardiomyocyte model for early cardiac derisking.
• Evaluate the effect of compounds on action potentials recorded from hiPSC-derived cardiomyocytes using manual patch screening.
• Chronic cardiotoxicity assay: hiPSC-derived cardiomyocytes to measure the cardiotoxic potential of test compounds.
• High-quality, cost effective and rapid turnaround GLP testing against hERG.

Please contact us if you would like further information on our Cardiac Safety Screening Services.